ondasdechoque.org
PT-BR

Plantar heel pain: a small pooled difference in morning pain · Review · 2005

How much does shockwave ease morning heel pain compared with placebo?

In this review of 11 trials, morning heel pain at about 12 weeks was slightly lower with shockwave than with placebo or a very low dose: less than half a point on a 0–10 scale, across 6 trials. In the 4 better-run trials the difference was smaller and could be due to chance.

Close to placebo, under half a point apart
trials
11
people with heel pain
1,290
trials combined for morning pain
6

Good to know: Device makers supported 3 of the 11 trials.

Thomson CE, Crawford F, Murray GD BMC Musculoskelet Disord, 2005 · Read the paper ↗

How this study worked

6 studiesOne answer
A review gathers earlier studies to answer one question.

What happened

studies
6
Compared with
Placebo shockwave or a very low dose

Morning heel pain vs placebo

Difference on a 0–10 pain scale · above zero means less pain with shockwave

Across 6 trials, morning pain was about 0.4 points lower with shockwave. In the 4 better-run trials the gap was about 0.2 points, with a range that includes no difference.
Show the numbers
Difference (points on a 0–10 pain scale)likely range
All 6 trials+0.420.02 to 0.83
4 better-run trials+0.21−0.29 to 0.7

What the trials used

Pooled trial regimens
Abt: Ossatron 1,000 ×2, 0.08 mJ/mm²; Buch: Epos Ultra 3,800 total, 0.03–0.36 mJ/mm²; Buchbinder: Epos Ultra 2,000–2,500 ×3, 0.02–0.33 mJ/mm²; Haake: Epos Ultra 4,000 ×3, 0.08 mJ/mm²; Ogden: Ossatron 1,500 total, 0.22 mJ/mm²; Speed: Sonocur Plus 1,500 ×3, 0.06 mJ/mm².
Controls
Pooled trials: absorbent block (Abt), absorbent foil (Buch), 300 versus 6,000–7,500 impulses (Buchbinder), polythene foil barrier (Haake), Styrofoam block (Ogden), focus outside the patient (Speed).
Local anaesthesia and guidance
Local anaesthetic in both groups: Abt, Buch, Haake, Ogden (different for placebo); none in Buchbinder or Speed. Ultrasound guidance in Buch, Buchbinder and Speed, not in Ogden, not stated in Abt and Haake.

Who took part

1,290 adults with heel pain, usually for over 6 months, in 11 trials up to 2003; some trials enrolled runners or people with heel spurs.

Side effects

Mostly mild redness, swelling, numbness or pain; one person tore the plantar fascia after treatment, after many earlier steroid injections.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults with plantar heel pain in 11 RCTs published 1996–2003 (1,290 patients); 6 trials pooled for morning pain at about 12 weeks. Pain lasted over 6 months in 10 trials; some trials enrolled runners, people with heel spurs or people being considered for surgery.

Morning (first-step) heel pain4 reported outcomes
01
About 12 weeks (Abt: first outcome at about 19 weeks)

Morning (first-step) heel pain

10 cm VAS, morning (first-step) pain cm on a 10-cm VAS

WMD0.42CI 95% 0.02 to 0.83p = 0.04

Shockwaves versus placebo or low-dose shockwaves

6 studies · Chi²=8.92, df=5, P=0.11; I²=43.9%

Fixed-effect weighted mean difference (RevMan)

-0.1Equal results 00.9

Pooled across 6 trials, the difference favoured shockwaves by 0.42 cm on a 10-cm scale; the authors considered this less than half a centimetre and not clinically meaningful. Individual trials ranged from −0.50 (Buchbinder) to 2.00 (Abt).

Analysis details and source

Positive values favour shockwaves per the Figure 2 axis. Figure 2 totals are 436 and 445 analysed, whereas the abstract states n=897; the participant count is left blank here. The figure does not state whether the means are final scores or improvements, and Haake values differ from Table 5. Abt SDs were derived from a p-value.

02
About 12 weeks (Abt: first outcome at about 19 weeks)

Morning pain, excluding Abt (imputed SDs)

10 cm VAS, morning (first-step) pain cm on a 10-cm VAS

WMD0.3CI 95% -0.12 to 0.72p not reported

Shockwaves versus control, Abt excluded

5 studies

Fixed-effect weighted mean difference (RevMan)

-0.2Equal results 00.8

Without the only trial with imputed variance, the pooled difference was 0.30 cm with an interval including zero.

Analysis details and source

Sensitivity analysis on 5 trials; p-value not reported.

03
About 12 weeks (Abt: first outcome at about 19 weeks)

Morning pain, higher-quality trials

10 cm VAS, morning (first-step) pain cm on a 10-cm VAS

WMD0.21CI 95% -0.29 to 0.7p = 0.41

Shockwaves versus control, quality score ≥4

4 studies

Fixed-effect weighted mean difference (RevMan)

-0.4Equal results 00.8

The four trials scoring 4 or more on the 6-point quality scale (Buchbinder, Haake, Speed, Buch) showed a small difference with an interval including zero.

Analysis details and source

Quality subgroup; fixed-effect model.

04
About 12 weeks (Abt: first outcome at about 19 weeks)

Morning pain, lower-quality trials

10 cm VAS, morning (first-step) pain qualitative finding

The two lower-quality trials (Abt and Ogden) gave a weighted mean difference reported as −0.90 (95% CI −1.62 to −0.19), p=0.01, “in favour of active treatment”.

Analysis details and source

Kept qualitative because the reported sign is opposite to the main analysis, where positive values favour shockwaves. The text calls these trials “less than four”, “less than three” and “three or above” in different places; both scored 3 in Table 1.

Secondary outcomes (not pooled)1 reported outcome
05
12 weeks or nearest reported point

Secondary outcomes (not pooled)

qualitative finding

Walking, pressure, night and rest pain, Roles and Maudsley, AOFAS and Maryland foot scores, SF-12 and SF-36 could not be pooled because measures differed. Six trials reported a favourable walking-pain result; pain at rest favoured shockwaves in four of five trials; the authors describe the other outcomes as equivocal.

Analysis details and source

Narrative summary from Table 5; vote counting of p-values, not an effect estimate.

Trials not pooled1 reported outcome
06
6 months (Rompe 2003); other times as reported

Trials not pooled

qualitative finding

Five trials (about 310 patients) were not pooled for lack of usable data, different timing or outcomes. Rompe 2003 in running athletes reported a morning-pain difference of 2.60 (95% CI 1.37 to 3.83) at 6 months.

Analysis details and source

The authors suggest large effects in the two smallest trials may reflect chance, small-study bias, failed blinding or true subgroup effects.

How treatment was delivered
Pooled trial regimens

Abt: Ossatron 1,000 ×2, 0.08 mJ/mm²; Buch: Epos Ultra 3,800 total, 0.03–0.36 mJ/mm²; Buchbinder: Epos Ultra 2,000–2,500 ×3, 0.02–0.33 mJ/mm²; Haake: Epos Ultra 4,000 ×3, 0.08 mJ/mm²; Ogden: Ossatron 1,500 total, 0.22 mJ/mm²; Speed: Sonocur Plus 1,500 ×3, 0.06 mJ/mm².

Controls

Pooled trials: absorbent block (Abt), absorbent foil (Buch), 300 versus 6,000–7,500 impulses (Buchbinder), polythene foil barrier (Haake), Styrofoam block (Ogden), focus outside the patient (Speed).

Local anaesthesia and guidance

Local anaesthetic in both groups: Abt, Buch, Haake, Ogden (different for placebo); none in Buchbinder or Speed. Ultrasound guidance in Buch, Buchbinder and Speed, not in Ogden, not stated in Abt and Haake.

HARMS & TOLERABILITY

Not pooled. Two trials did not report adverse events. Buchbinder: one person per arm had pain for a week; in the active arm one reported heat and numbness and one bruising; in the placebo arm one reported burning. Ogden: 38 procedure-related complications, 18 in the active arm, mostly mild numbness or tingling; one plantar fascia rupture 4 weeks after active treatment in a patient with multiple prior cortisone injections. Haake: more side effects with active treatment, OR 2.26 (95% CI 1.02 to 5.18), mainly skin reddening, pain and local swelling. Two trials described treatment as unpleasant; Krischek reported no adverse events.

LIMITS OF THE ANALYSIS

Count inconsistency: the abstract and Discussion state 897 patients in the pooled analysis, while Figure 2 lists 436 shockwave and 445 control participants. Speed 2003 appears as 42 shockwave and 46 control in Figure 2, while Table 2 gives 26:20 women:men for treatment and 25:17 for control (extractor observation).

Direction and data: Figure 2 is captioned as VAS scores but plots positive differences as favouring treatment, while several shockwave means are higher than control; Haake values in Figure 2 differ from Table 5. The low-quality subgroup is reported with the opposite sign.

Methods: placebo and subtherapeutic-dose controls combined; local anaesthesia in some trials; Abt outcome at about 19 weeks with imputed SDs; quality score thresholds described inconsistently; five of 11 trials not pooled; searches to September 2004. The text lists Rompe [30] as a low-dose control and Rompe [32] as placebo, whereas Table 4 shows a 1-cm gap for [30] and 3,000 versus 30 impulses for [32].

Industry sponsorship: device makers supported three included trials (Haake supplied machine; Buch sponsored by Dornier; Ogden linked to HealthTronics), and Buch and Ogden were used for FDA approval; six trials made no declaration. The authors declared no competing interests; review funding is not stated.

Supplement: Additional file 1 (full EMBASE and MEDLINE search strategies) was not part of the local PDF and was not read.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Count inconsistency: the abstract and Discussion state 897 patients in the pooled analysis, while Figure 2 lists 436 shockwave and 445 control participants. Speed 2003 appears as 42 shockwave and 46 control in Figure 2, while Table 2 gives 26:20 women:men for treatment and 25:17 for control (extractor observation).
  • Direction and data: Figure 2 is captioned as VAS scores but plots positive differences as favouring treatment, while several shockwave means are higher than control; Haake values in Figure 2 differ from Table 5. The low-quality subgroup is reported with the opposite sign.
  • Methods: placebo and subtherapeutic-dose controls combined; local anaesthesia in some trials; Abt outcome at about 19 weeks with imputed SDs; quality score thresholds described inconsistently; five of 11 trials not pooled; searches to September 2004. The text lists Rompe [30] as a low-dose control and Rompe [32] as placebo, whereas Table 4 shows a 1-cm gap for [30] and 3,000 versus 30 impulses for [32].
  • Industry sponsorship: device makers supported three included trials (Haake supplied machine; Buch sponsored by Dornier; Ogden linked to HealthTronics), and Buch and Ogden were used for FDA approval; six trials made no declaration. The authors declared no competing interests; review funding is not stated.
  • Supplement: Additional file 1 (full EMBASE and MEDLINE search strategies) was not part of the local PDF and was not read.
Research review

Source-linked critical reading

Systematic review and meta-analysis

Reading depthMaterial consulted
Technical source record

Complete local PDF read (all 11 pages): methods, results, Tables 1–6, Figures 1–2, discussion, conclusion, competing interests and references. Additional file 1 (search strategies) was not available locally.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Systematic review and meta-analysis of RCTs: Cochrane registers (2003), MEDLINE 1966, EMBASE and CINAHL 1982 to September 2004, plus reference lists; two German-language trials were translated. Two reviewers selected and extracted; 6-point quality score; fixed-effect RevMan pooling planned unless heterogeneity. 11 trials included, 6 pooled for the a priori primary outcome, morning pain.

Participants and setting

Adults with plantar heel pain in 11 RCTs published 1996–2003 (1,290 patients); 6 trials pooled for morning pain at about 12 weeks. Pain lasted over 6 months in 10 trials; some trials enrolled runners, people with heel spurs or people being considered for surgery.

Treatment

Shockwaves from several devices (Ossatron, Epos Ultra, Osteostar, Sonocur Plus, Orthima) at low or high energy, 500 to 4,000 impulses per session, 1 to 6 sessions; the review does not classify devices as focused or radial.

Comparison

The text counts 8 placebo-controlled trials and 3 with a low, presumed subtherapeutic dose. Controls in Table 4: absorbent block or foil, polythene barrier, Styrofoam block, reflecting pad, 1-cm gap, focus outside the patient, or far fewer impulses (300 or 30). Local anaesthetic was given to both groups in 4 of the 6 pooled trials.

Outcomes and timing

Primary: morning (first-step) pain on a 10-cm VAS at 12 weeks or nearest point. Secondary: walking, pressure and rest pain, disability, quality of life and adverse events; these could not be pooled.

What the results show

Six trials: weighted mean difference 0.42 cm (95% CI 0.02 to 0.83), p=0.04, favouring shockwaves; I²=43.9%, fixed effect. Individual trials ranged from −0.50 to 2.00. Excluding the trial with imputed SDs: 0.30 (−0.12 to 0.72). Four higher-quality trials: 0.21 (−0.29 to 0.70), p=0.41. The two lower-quality trials gave a larger, significant difference (reported as −0.90, −1.62 to −0.19, with a reversed sign). Secondary outcomes were summarized only by p-values.

Harms

Not pooled. Two trials did not report adverse events. Buchbinder: one person per arm had pain for a week; in the active arm one reported heat and numbness and one bruising; in the placebo arm one reported burning. Ogden: 38 procedure-related complications, 18 in the active arm, mostly mild numbness or tingling; one plantar fascia rupture 4 weeks after active treatment in a patient with multiple prior cortisone injections. Haake: more side effects with active treatment, OR 2.26 (95% CI 1.02 to 5.18), mainly skin reddening, pain and local swelling. Two trials described treatment as unpleasant; Krischek reported no adverse events.

Limits and disclosures

The 897 patients stated do not match the 436 and 445 in Figure 2; Figure 2 direction and Haake values conflict with the caption and Table 5; quality thresholds are described inconsistently and the low-quality estimate has a reversed sign. Placebo and low-dose controls were combined, local anaesthesia varied, and Abt contributed a 19-week outcome with imputed SDs. Three included trials had industry support. Authors declared no competing interests; Additional file 1 was not read.

Application to care

Reflects trials of mostly long-standing heel pain up to 2003 with older devices and frequent local anaesthesia. It gives a pooled morning-pain difference at about 12 weeks; it says little about function, later follow-up, or newer regimens given without anaesthesia.

What remains to be tested

Trials reporting means with variance for morning pain and disability, separating sham from low-dose controls and device types, with prespecified clinically important differences.

THE ORIGINAL SOURCE

Read the original article.

The effectiveness of extra corporeal shock wave therapy for plantar heel pain: a systematic review and meta-analysis.

Thomson CE, Crawford F, Murray GD. · BMC Musculoskelet Disord · 2005

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →